Liver transplantation (LT) using allografts from hepatitis C virus (HCV)-viremic/nucleic acid testing-positive donors’ (DNAT+) organs into HCV-aviremic recipients (rHCV-) has been limited due to nearly universal HCV transmission and concerns regarding availability, safety, and efficacy post-LT with direct-acting antiviral (DAAs) therapy. We report our experience of LT using DNAT+ organs into rHCV- as a routine standard of care. Following verification of DAAs access, absence of critical drug-drug interactions (DDIs) with DAAs, and informed consent, allocated DNAT+ organs were offered to patients on the waiting list for LT irrespective of recipient HCV status. Between June 2018 and December 2019, 292/339 rHCV- received a LT. 47 patients were excluded from analysis due to recipient HCV viremia, refusal to receive DNAT+ organs, or inability to receive DAAs therapy post-LT. 61 rHCV- received a DNAT+ liver (study group), and 231 rHCV- received a DNAT- liver (control group). Recipient and donor characteristics as well as 1-year post-LT patient and graft survival were similar between groups. In the study group, 4 patients died, and 1 patient required retransplantation within the first year post-LT (all unrelated to HCV); 56 patients received DAAs therapy, with a median time from LT to the start of DAAs treatment of 66.9 days (interquartile range [IQR], 36-68.5), and 51 patients completed DAAs treatment, all achieving sustained virologic response for 12 or more weeks (SVR-12) (1 patient required retreatment due to relapse following initial DAA therapy). No patients had evidence of fibrosing cholestatic hepatitis (FCH) or extrahepatic manifestations of HCV. This report indicates that transplantation of DNAT+ livers into rHCV- and subsequent DAAs therapy is associated with clinical outcomes comparable to those achieved with DNAT- allografts.This article is protected by copyright. All rights reserved.